[{"address1": "828 Winter Street", "address2": "Suite 300", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 524 2466", "website": "https://xiliotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rene  Russo BCPS, Pharm.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 875130, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Frankenfield", "age": 42, "title": "Chief Operating Officer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 704848, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Katarina  Luptakova M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 591917, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin M. Brennan", "age": 54, "title": "Senior VP of Finance & Accounting", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uli  Bialucha Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Hensley", "title": "Chief Legal Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott  Coleman Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.8297, "open": 0.8327, "dayLow": 0.8096, "dayHigh": 0.8547, "regularMarketPreviousClose": 0.8297, "regularMarketOpen": 0.8327, "regularMarketDayLow": 0.8096, "regularMarketDayHigh": 0.8547, "beta": -0.199, "forwardPE": -1.2240298, "volume": 146052, "regularMarketVolume": 146052, "averageVolume": 586996, "averageVolume10days": 515030, "averageDailyVolume10Day": 515030, "bid": 0.7881, "ask": 0.8618, "bidSize": 100, "askSize": 100, "marketCap": 37493416, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 1.93, "priceToSalesTrailing12Months": 8.115458, "fiftyDayAverage": 1.0234, "twoHundredDayAverage": 0.98503, "currency": "USD", "enterpriseValue": -16793984, "floatShares": 22620385, "sharesOutstanding": 45718100, "sharesShort": 384094, "sharesShortPriorMonth": 175269, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0084, "heldPercentInsiders": 0.39060003, "heldPercentInstitutions": 0.28361, "shortRatio": 0.46, "shortPercentOfFloat": 0.0101, "impliedSharesOutstanding": 45718100, "bookValue": 0.477, "priceToBook": 1.7192873, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -62803000, "trailingEps": -1.55, "forwardEps": -0.58, "enterpriseToRevenue": -3.635, "enterpriseToEbitda": 0.269, "52WeekChange": 0.22571003, "SandP52WeekChange": 0.23809385, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XLO", "underlyingSymbol": "XLO", "shortName": "Xilio Therapeutics, Inc.", "longName": "Xilio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1634909400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a29df73e-2ef5-3eed-8f1d-9d3cdeb4d4fb", "messageBoardId": "finmb_365333564", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.8201, "targetHighPrice": 5.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.5, "targetMedianPrice": 4.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 61259000, "totalCashPerShare": 1.394, "ebitda": -62428000, "totalDebt": 8415000, "quickRatio": 1.611, "currentRatio": 1.665, "totalRevenue": 4620000, "debtToEquity": 40.121, "revenuePerShare": 0.105, "returnOnAssets": -0.52579, "returnOnEquity": -1.70958, "grossProfits": 4620000, "freeCashflow": -3042250, "operatingCashflow": -17648000, "grossMargins": 1.0, "operatingMargins": -6.5413203, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]